Difference between revisions of "Acute myeloid leukemia trial demographics"

From HemOnc.org - A Hematology Oncology Wiki
Jump to navigation Jump to search
(Created page with "{| class="wikitable sortable" style="width: 100%; text-align:center;" !style="width: 17%"|Study !style="width: 15%"|Arm !style="width: 17%"|Age, median (range) !style="width:...")
 
m
 
(2 intermediate revisions by the same user not shown)
Line 7: Line 7:
 
!style="width: 17%"|Performance Status
 
!style="width: 17%"|Performance Status
 
|-
 
|-
|[http://www.bloodjournal.org/content/79/2/313 Wiernik et al. 1992]
+
|[https://doi.org/10.1182/blood.V79.2.313.313 Wiernik et al. 1992]
 
|[[Acute_myeloid_leukemia#7.2B3d_.28standard-dose.29|7+3d (standard-dose)]]
 
|[[Acute_myeloid_leukemia#7.2B3d_.28standard-dose.29|7+3d (standard-dose)]]
 
|55 (NR)
 
|55 (NR)
Line 14: Line 14:
 
|ECOG 0-1: 86%
 
|ECOG 0-1: 86%
 
|-
 
|-
|[http://www.bloodjournal.org/content/79/2/313 Wiernik et al. 1992]
+
|[https://doi.org/10.1182/blood.V79.2.313.313 Wiernik et al. 1992]
 
|[[Acute_myeloid_leukemia#7.2B3i|7+3i]]
 
|[[Acute_myeloid_leukemia#7.2B3i|7+3i]]
 
|56 (NR)
 
|56 (NR)
Line 49: Line 49:
 
|ECOG 0-1: 88%
 
|ECOG 0-1: 88%
 
|-
 
|-
|[http://www.bloodjournal.org/content/118/14/3832.long ADcomparison]
+
|[https://doi.org/10.1182/blood-2011-06-361410 ADcomparison]
 
|[[Acute_myeloid_leukemia#7.2B3d_.28standard-dose.29|7+3d (standard-dose)]]
 
|[[Acute_myeloid_leukemia#7.2B3d_.28standard-dose.29|7+3d (standard-dose)]]
|43 (15-60)
+
|43 (15-60)<sup>a</sup>
 
|48/52
 
|48/52
 
|NR
 
|NR
 
|KPS 90-100%: 80%
 
|KPS 90-100%: 80%
 
|-
 
|-
|[http://www.bloodjournal.org/content/118/14/3832.long ADcomparison]
+
|[https://doi.org/10.1182/blood-2011-06-361410 ADcomparison]
 
|[[Acute_myeloid_leukemia#7.2B3d_.28high-dose.29|7+3d (high-dose)]]
 
|[[Acute_myeloid_leukemia#7.2B3d_.28high-dose.29|7+3d (high-dose)]]
|43 (15-60)
+
|43 (15-60)<sup>a</sup>
 
|60/40
 
|60/40
 
|NR
 
|NR
Line 64: Line 64:
 
|-
 
|-
 
|}
 
|}
 +
''<sup>a</sup>Age is not reported separately by arm.
 +
 +
'''This work is supported in part by [https://reporter.nih.gov/search/bweQKIeIwk-kOtL_oHSGSw/project-details/10705015 NCI U24 CA265879].'''
  
 
[[Category:General reference pages]]
 
[[Category:General reference pages]]

Latest revision as of 23:01, 27 June 2024

Study Arm Age, median (range) Sex (%M/%F) Race Performance Status
Wiernik et al. 1992 7+3d (standard-dose) 55 (NR) 57/43 NR ECOG 0-1: 86%
Wiernik et al. 1992 7+3i 56 (NR) 56/44 NR ECOG 0-1: 87%
ECOG E1900 7+3d (standard-dose) 47 (17-60) 52/48 NR NR
ECOG E1900 7+3d (high-dose) 48 (18-60) 50/50 NR NR
HOVON 43 AML/SAKK 30/01 7+3d (standard-dose) 67 (60-79) 57/43 NR ECOG 0-1: 88%
HOVON 43 AML/SAKK 30/01 7+3d (high-dose) 67 (60-83) 53/47 NR ECOG 0-1: 88%
ADcomparison 7+3d (standard-dose) 43 (15-60)a 48/52 NR KPS 90-100%: 80%
ADcomparison 7+3d (high-dose) 43 (15-60)a 60/40 NR KPS 90-100%: 82.5%

aAge is not reported separately by arm.

This work is supported in part by NCI U24 CA265879.